ONTAK (denileukin difitox, DAB389IL-2)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Lymphoma, T-Cell, Cutaneous
Conditions
Lymphoma, T-Cell, Cutaneous
Trial Timeline
May 1, 2001 → Jan 1, 2006
NCT ID
NCT00211198About ONTAK (denileukin difitox, DAB389IL-2)
ONTAK (denileukin difitox, DAB389IL-2) is a approved stage product being developed by Eisai for Lymphoma, T-Cell, Cutaneous. The current trial status is completed. This product is registered under clinical trial identifier NCT00211198. Target conditions include Lymphoma, T-Cell, Cutaneous.
What happened to similar drugs?
17 of 20 similar drugs in Lymphoma, T-Cell, Cutaneous were approved
Approved (17) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00211198 | Approved | Completed |
Competing Products
20 competing products in Lymphoma, T-Cell, Cutaneous